DaisyAI Market Position Synthesis

How we map to top-tier VC thinking across Bessemer, a16z, and Battery Ventures — correlated with our Premera engagement.

Date: 2026-02-10

The Short Version

Three of the most sophisticated healthcare investors in the market are independently describing the same opportunity — and it's the one we're executing on. We're not adjacent to the thesis. We ARE the thesis.

What Top-Tier VCs Are Saying

Bessemer: "Payers are about to go through a massive AI adoption wave"

Prediction #1 in their State of Health AI 2026: payers will feel pressure from providers to catch up on AI
Specific use cases named: prior authorization automation, concurrent utilization review, claims documentation
The driver: providers adopted AI first (ambient scribes, coding optimization), leading to upcoding and better revenue capture. Payer margins are getting squeezed. Payers must respond.
The business model they're excited about: "AI-services-as-software" — delivering service-level outcomes at software-level margins (70-80%+)
The growth pattern: Health AI companies hitting $100M ARR in <5 years (vs. 10+ for traditional healthcare software)
The framework (Health AI X Factor): velocity, revenue durability, AI productivity, platform expansion from a wedge

a16z: "Healthcare infrastructure is the most valuable layer, and it's all legacy"

Infrastructure companies collectively worth $160B+ — the most durable businesses in healthcare
Most built on legacy tech: no APIs, faxes, manual labor, fragile systems
Great infrastructure sits at: high-volume transaction nodes, payment flow adjacency, multi-stakeholder connective tissue, network effects
Clinical interoperability is a whitespace opportunity — clinical data exchange between payers and providers barely exists as modern infrastructure
AI is the lever for upstarts to unseat entrenched incumbents
"Could result in the creation of an infrastructure business that could ultimately become the biggest company in the world"

Battery Ventures: "FDE is how you get adoption, payers are feeling the squeeze"

Olivia Henkoff (80% healthcare focus, 6 years at Battery): "FDE is the smart decision in this category — if you don't have the FDE you're probably not going to get adoption"
Ambient scribes → upcoding → UM is getting harder for payers (unsolicited market tailwind confirmation)
Organizations are avoiding point solutions, moving toward consolidation — want help building, not buying
Backend/API integration preferred over new UI — stickiness comes from savings, not workflow
DaisyAI is "right down the fairway" for investable opportunities
Optera (6-12 months ahead, selling to payers) as direct FDE comp — Battery is watching this category form in real time

How Premera Validates Every Thesis

VC Thesis	Premera Evidence
Bessemer: Payers catching up on AI	Premera has 12 UM AI initiatives, capacity-constrained, pushed year-1 items to year-2. Literally asking for help accelerating.
Bessemer: AI-services-as-software model	Our engagement: custom development + ongoing platform. FDE wedge with software-margin potential.
Bessemer: Prior auth + concurrent review as key use cases	Premera wants exactly this — initial prior auth is their #1 priority, concurrent review is the gap we demoed.
a16z: Legacy infrastructure is fragile	Premera's UM still runs on ADT feeds updated every 15 min, PDF packets, phone calls. Nurses spending 20+ min per review digging through dense documents.
a16z: High-volume transaction node near payment flow	Every UM review is a financial decision about whether a claim gets paid. Millions of reviews annually across their WA and AK markets.
a16z: Clinical interoperability is whitespace	We're building the clinical data processing layer: ADT → structured summary → UM flags → nurse workflow. That IS clinical interoperability infrastructure between payer and provider.
a16z: AI as lever for upstarts vs. incumbents	Premera explicitly choosing us over building internally or buying from established vendors. Colt: "We need expertise like you all have to expand our capacity."
Battery: FDE is the adoption model	Premera doesn't want a product. They want us embedded — "do some sort of contract with you all and expand our capacity." Work in their environment, not ours.
Battery: Backend > UI	Colt suggested we might not need a UI. Work via APIs and data structuring behind the scenes. Exactly what Battery says works.
Battery: Payer pressure from upcoding	Premera has ~12 UM initiatives BECAUSE utilization pressure is rising. They need to process more, faster, with better accuracy.

Where We Sit in the Frameworks

Bessemer's Health AI X Factor (4 pillars)

1. Continuous hyper-growth velocity

Too early to measure — pre-revenue. But: first client about to close, second in the wing, 6-month pipeline building. The velocity will come from the FDE model's ability to land and expand within a single payer (12 initiatives at Premera alone = massive expansion opportunity).
Status: Can't prove yet. Premera contract is the proof point.

2. Revenue durability through defensibility

FDE creates deep integration — once embedded in their environment, data systems, and team workflows, switching cost is high.
Premera parallel: we'll be connected to their ADT feeds, integrated into their tools, trained their nurses. Ripping us out means rebuilding.
The a16z infrastructure thesis amplifies this: if we become part of their clinical data processing infrastructure, we're mission-critical.
Status: Structural advantage from the model. Not yet proven at scale.

3. AI productivity → software-like margins

Current model is consulting-heavy (FDE). Margins start lower. But: core analytical layer is reusable across payers. Each deployment builds the platform.
Revenue model (from Tau call): SaaS fee 5-10% + implementation fee + maintenance/licensing ~50-60% of contract. Maintenance/licensing portion IS software margin.
Status: Trajectory is right. Need to execute 3-5 clients to prove the margin expansion.

4. Point solution to platform expansion

UM is the wedge. Premera has 12 AI initiatives — we land on one, prove value, expand across their stack. That's the exact motion Bessemer describes.
a16z amplifies: we're not just expanding within one payer — we're building infrastructure that works across the payer-provider boundary. The platform IS the clinical interoperability layer.
Status: The expansion opportunity is visible (12 initiatives). Haven't executed it yet.

a16z Infrastructure Checklist

Characteristic	DaisyAI	Assessment
High-volume transaction node	UM reviews — millions annually per large payer	Yes
Tied to payment flow	Every review is a pay/deny decision	Yes
Connective tissue between stakeholders	Payer ↔ Provider clinical data exchange	Yes
System of record potential	Clinical review outputs, UM flag data, analytics	Emerging
Network effects	Not yet — single-payer. Could emerge with multi-payer data + provider-side adoption	Future
High gross margin potential	FDE starts lower, but platform components trend toward software margins	Trajectory
Regulatory tailwinds	CMS prior auth rules, AI governance frameworks emerging	Yes

The Narrative Gap

We're doing the right thing. The market is confirming it from every angle. But there's a gap between what we're DOING and how we DESCRIBE it. This came up in the Tau call ("wrapper on LLM" fear from the blurb) and the NextGen call (Deborah wanted a clearer end-state vision).

What we say now: "We build AI tools for payer utilization management" What we should say: "We're building next-generation payer-provider infrastructure, starting with UM. We go in as embedded engineers, build the clinical data processing layer, and become the AI backbone of their operations. The FDE model is how we get embedded. The infrastructure is what compounds."

That story connects:

Bessemer's X Factor (wedge → platform)
a16z's infrastructure thesis (high-value node, payment adjacency, multi-stakeholder)
Battery's FDE validation (adoption model)
Premera's reality (12 initiatives, capacity gap, year-2 → year-1 acceleration)

Honest Assessment

What's strong:

Market timing: 7/7 investors validated "why now." Bessemer and a16z are writing reports about our exact market. Zero pushback.
Model fit: FDE is being validated by VCs (Battery, Bessemer) as THE adoption model for healthcare AI. Not a compromise — an advantage.
Premera as proof: A real payer, with real AI infrastructure, asking us to accelerate their roadmap. Not a pilot — a working engagement.
Team: Universal positive signal (7/7 calls). Both founders build. Bootstrapped to first client.
Payer-first rationale: Clear, accepted every time it's tested.

What's missing:

Revenue. Everything else is narrative until there's a signed contract and cash. Premera is the bridge.
The infrastructure story. We have the wedge (FDE + UM) but haven't articulated the platform vision crisply enough for investors who want to see the $1B outcome.
TAM numbers. Still don't have specific market sizing. Bessemer and a16z provide framing but we need our own bottom-up model.
Multi-client proof. One client is a case study. Three clients is a pattern. We need to show the model repeats.
Written materials. The verbal pitch is strong. The deck/blurb triggers "wrapper" fear. Gap between how we talk and how we write.

What's at risk:

Speed. These market windows don't stay open forever. If we take too long to close Premera and get to 3-4 clients, the category will fill up. Bessemer notes companies hitting $100M ARR in <5 years — speed matters.
Premera dependency. One client concentration. Need the second and third to de-risk the story.
Foundation model companies. OpenAI and Anthropic are starting to work directly with health systems (Battery flagged this). If they build good-enough clinical AI tools, the "build it yourself" path gets easier without us.

Bottom Line

Top-tier VCs are describing a market opportunity that maps almost perfectly to what we're building. The payer AI wave is real (Bessemer Prediction #1), the infrastructure opportunity is massive (a16z), and the FDE model is the right go-to-market (Battery). Premera isn't just our first client — it's a living case study of every thesis these firms are publishing about.

We're not ahead of the market. We're not behind. We're exactly where we should be — at the moment where the thesis meets execution. The Premera contract turns narrative into proof. Everything accelerates from there.